333 related articles for article (PubMed ID: 9774334)
21. Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex.
Wang F; Lu W; McKeehan K; Mohamedali K; Gabriel JL; Kan M; McKeehan WL
Biochemistry; 1999 Jan; 38(1):160-71. PubMed ID: 9890894
[TBL] [Abstract][Full Text] [Related]
22. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis.
Aviezer D; Cotton S; David M; Segev A; Khaselev N; Galili N; Gross Z; Yayon A
Cancer Res; 2000 Jun; 60(11):2973-80. PubMed ID: 10850445
[TBL] [Abstract][Full Text] [Related]
23. Heparan sulfate fibroblast growth factor receptor complex: structure-function relationships.
McKeehan WL; Kan M
Mol Reprod Dev; 1994 Sep; 39(1):69-81; discusison 81-2. PubMed ID: 7999363
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
26. Signaling via fibroblast growth factor receptor-1 is dependent on extracellular matrix in capillary endothelial cell differentiation.
Kanda S; Tomasini-Johansson B; Klint P; Dixelius J; Rubin K; Claesson-Welsh L
Exp Cell Res; 1999 Apr; 248(1):203-13. PubMed ID: 10094827
[TBL] [Abstract][Full Text] [Related]
27. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.
Thompson AM; Delaney AM; Hamby JM; Schroeder MC; Spoon TA; Crean SM; Showalter HD; Denny WA
J Med Chem; 2005 Jul; 48(14):4628-53. PubMed ID: 16000000
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
Zhu Z; Rockwell P; Lu D; Kotanides H; Pytowski B; Hicklin DJ; Bohlen P; Witte L
Cancer Res; 1998 Aug; 58(15):3209-14. PubMed ID: 9699643
[TBL] [Abstract][Full Text] [Related]
30. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
[TBL] [Abstract][Full Text] [Related]
31. Direct FGF receptor 1 activation through an anti-idiotypic strategy mimicks the biological activity of FGF-2 and inhibits the progression of the bladder carcinoma derived from NBT-II cells.
Malavaud B; Pedron S; Sordello S; Mazerolles C; Billottet C; Thiery JP; Jouanneau J; Plouët J
Oncogene; 2004 Sep; 23(40):6769-78. PubMed ID: 15273729
[TBL] [Abstract][Full Text] [Related]
32. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
[TBL] [Abstract][Full Text] [Related]
33. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
[TBL] [Abstract][Full Text] [Related]
34. Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2.
Billottet C; Janji B; Thiery JP; Jouanneau J
Oncogene; 2002 Nov; 21(53):8128-39. PubMed ID: 12444548
[TBL] [Abstract][Full Text] [Related]
35. VEGF is major stimulator in model of choroidal neovascularization.
Kwak N; Okamoto N; Wood JM; Campochiaro PA
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3158-64. PubMed ID: 10967078
[TBL] [Abstract][Full Text] [Related]
36. Selection of peptide ligands binding to fibroblast growth factor receptor 1.
Fan H; Duan Y; Zhou H; Li W; Li F; Guo L; Roeske RW
IUBMB Life; 2002 Aug; 54(2):67-72. PubMed ID: 12440521
[TBL] [Abstract][Full Text] [Related]
37. Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells.
Antoine M; Wirz W; Tag CG; Mavituna M; Emans N; Korff T; Stoldt V; Gressner AM; Kiefer P
Growth Factors; 2005 Jun; 23(2):87-95. PubMed ID: 16019430
[TBL] [Abstract][Full Text] [Related]
38. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
[TBL] [Abstract][Full Text] [Related]
39. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.
Miao HQ; Ornitz DM; Aingorn E; Ben-Sasson SA; Vlodavsky I
J Clin Invest; 1997 Apr; 99(7):1565-75. PubMed ID: 9120000
[TBL] [Abstract][Full Text] [Related]
40. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.
Trumpp-Kallmeyer S; Rubin JR; Humblet C; Hamby JM; Showalter HD
J Med Chem; 1998 May; 41(11):1752-63. PubMed ID: 9599227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
